🚀 #WCLC 2025: DLL3-Directed therapy shows encouraging results in relapsed SCLC. Phase I trial of SHR-4849 reached 59.5% overall response and up to 77.8% at higher doses, without dose-limiting toxicities.
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
WCLC 2025: DLL3 Therapy Shows Promise in Relapsed SCLC
A Phase 1 trial of the DLL3-targeted antibody-drug conjugate SHR-4849 shows high response rates and manageable safety in relapsed small cell lung cancer, supporting further clinical development.
www.emjreviews.com
September 9, 2025 at 6:34 PM
🚀 #WCLC 2025: DLL3-Directed therapy shows encouraging results in relapsed SCLC. Phase I trial of SHR-4849 reached 59.5% overall response and up to 77.8% at higher doses, without dose-limiting toxicities.
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
www.emjreviews.com/en-us/amj/re...
#AMJOncology #LungCancerResearch
New insights: Targeting the agrin-EGFR interaction could lead to new treatment options for advanced EGFR+ #lungcancer. Learn more about this study: advanced.onlinelibrary.wiley.com/doi/10.1002/... #EGFR #LungCancerResearch #LCSM
An Agrin–YAP/TAZ Rigidity Sensing Module Drives EGFR‐Addicted Lung Tumorigenesis
The study identifies agrin-EGFR mechanotransduction as a critical driver of lung adenocarcinoma which enhances EGFR signaling through an integrin-FAK-actomyosin dependent positive feedback on YAP/TAZ....
advanced.onlinelibrary.wiley.com
April 1, 2025 at 7:03 AM
New insights: Targeting the agrin-EGFR interaction could lead to new treatment options for advanced EGFR+ #lungcancer. Learn more about this study: advanced.onlinelibrary.wiley.com/doi/10.1002/... #EGFR #LungCancerResearch #LCSM
Show your love by supporting #lungcancerresearch. 💖 🔬 LCRF.org/donate
Donate to LCRF Main Donation Form
Help us reach our goal! Your support will make a meaningful difference. Every contribution brings us closer to success. Join us today and be part of something impactful.
LCRF.org
February 14, 2025 at 2:01 PM
Show your love by supporting #lungcancerresearch. 💖 🔬 LCRF.org/donate
In honor of Women's History Month, we’re shining a spotlight on the brilliant early career researchers who are leading the charge in lung cancer research. Their groundbreaking work is paving the way for new treatments and a brighter future for lung cancer patients. #LungCancerResearch
March 13, 2025 at 1:13 AM
In honor of Women's History Month, we’re shining a spotlight on the brilliant early career researchers who are leading the charge in lung cancer research. Their groundbreaking work is paving the way for new treatments and a brighter future for lung cancer patients. #LungCancerResearch
New insights from 122 cases unveil genomic & epigenomic clues to stage I NSCLC recurrence—20-40% risk, 57 recurrent. Key: solid/micropapillary hist. #LungCancerResearch PMID:39929832, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-024-55068-2 🧪
February 23, 2025 at 11:10 AM
New insights from 122 cases unveil genomic & epigenomic clues to stage I NSCLC recurrence—20-40% risk, 57 recurrent. Key: solid/micropapillary hist. #LungCancerResearch PMID:39929832, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-024-55068-2 🧪
As the leading #lungcancerresearch organization in the country and the largest nonprofit funder of lung cancer research, LUNGevity is taking decisive steps in response to recent government actions that threaten #lungcancer treatment and ongoing care. www.lungevity.org/protecting-p...
April 16, 2025 at 3:10 PM
As the leading #lungcancerresearch organization in the country and the largest nonprofit funder of lung cancer research, LUNGevity is taking decisive steps in response to recent government actions that threaten #lungcancer treatment and ongoing care. www.lungevity.org/protecting-p...
🩸 We know, we cannot stop talking about the EQUAL study — the assay this, the blood test that... but you might be wondering:
How does this blood test actually work?
👇Find out!
(And trust us, it's so cool)
#LungCancerResearch #BloodTestBreakdown #EQUALStudy #ctDNA #CancerCare
How does this blood test actually work?
👇Find out!
(And trust us, it's so cool)
#LungCancerResearch #BloodTestBreakdown #EQUALStudy #ctDNA #CancerCare
April 25, 2025 at 8:42 PM
🩸 We know, we cannot stop talking about the EQUAL study — the assay this, the blood test that... but you might be wondering:
How does this blood test actually work?
👇Find out!
(And trust us, it's so cool)
#LungCancerResearch #BloodTestBreakdown #EQUALStudy #ctDNA #CancerCare
How does this blood test actually work?
👇Find out!
(And trust us, it's so cool)
#LungCancerResearch #BloodTestBreakdown #EQUALStudy #ctDNA #CancerCare
LCRF's fall e-newsletter is here, with updates about research, education, events, and more. Check your inbox, or read it at LCRF.org/enews.
#LungCancer #LungCancerResearch
#LungCancer #LungCancerResearch
LCRF e-news - Lung Cancer Research Foundation
LCRF.org
November 19, 2024 at 12:10 AM
LCRF's fall e-newsletter is here, with updates about research, education, events, and more. Check your inbox, or read it at LCRF.org/enews.
#LungCancer #LungCancerResearch
#LungCancer #LungCancerResearch
Funding lung cancer research benefits everyone with lungs. #LungCancerResearch #LungCancerAwareness #ResearchFunding
lcfamerica.org/lung-cancer-...
lcfamerica.org/lung-cancer-...
June 19, 2025 at 12:35 AM
Funding lung cancer research benefits everyone with lungs. #LungCancerResearch #LungCancerAwareness #ResearchFunding
lcfamerica.org/lung-cancer-...
lcfamerica.org/lung-cancer-...
Exploring the Mechanism of Zilongjin in Treating Lung Adenocarcinoma Based on Network Pharmacology Combined with Experimental Verification
www.dl.begellhouse.com/journals/2ff...
#TraditionalMedicine #LungCancerResearch #NetworkPharmacology #ExperimentalTherapeutics
www.dl.begellhouse.com/journals/2ff...
#TraditionalMedicine #LungCancerResearch #NetworkPharmacology #ExperimentalTherapeutics
May 13, 2025 at 3:05 PM
Exploring the Mechanism of Zilongjin in Treating Lung Adenocarcinoma Based on Network Pharmacology Combined with Experimental Verification
www.dl.begellhouse.com/journals/2ff...
#TraditionalMedicine #LungCancerResearch #NetworkPharmacology #ExperimentalTherapeutics
www.dl.begellhouse.com/journals/2ff...
#TraditionalMedicine #LungCancerResearch #NetworkPharmacology #ExperimentalTherapeutics
Run the Big Sur International Marathon with Team LUNGevity
@lungevity.bsky.social
oncodaily.com/blog/big-sur...
#BigSurInternationalMarathon #Cancer #Oncology #FightAgainstCancer #GlobalAwareness #OncoDaily #LungCancerResearch #LUNGevityFoundation
@lungevity.bsky.social
oncodaily.com/blog/big-sur...
#BigSurInternationalMarathon #Cancer #Oncology #FightAgainstCancer #GlobalAwareness #OncoDaily #LungCancerResearch #LUNGevityFoundation
Run the Big Sur International Marathon with Team LUNGevity - OncoDaily
Run the Big Sur International Marathon with Team LUNGevity / Big Sur International Marathon, cancer, fight against cancer, Global awareness, Global fight
oncodaily.com
March 14, 2025 at 5:19 PM
Run the Big Sur International Marathon with Team LUNGevity
@lungevity.bsky.social
oncodaily.com/blog/big-sur...
#BigSurInternationalMarathon #Cancer #Oncology #FightAgainstCancer #GlobalAwareness #OncoDaily #LungCancerResearch #LUNGevityFoundation
@lungevity.bsky.social
oncodaily.com/blog/big-sur...
#BigSurInternationalMarathon #Cancer #Oncology #FightAgainstCancer #GlobalAwareness #OncoDaily #LungCancerResearch #LUNGevityFoundation
Preserving funding for cancer research is a nonpartisan issue. Lend your voice to the fight to restore #lungcancerresearch funding. #lcsm Link in thread.
May 22, 2025 at 3:30 PM
Preserving funding for cancer research is a nonpartisan issue. Lend your voice to the fight to restore #lungcancerresearch funding. #lcsm Link in thread.
Dr. Kellie Smith highlights the critical issue of underfunding in lung cancer research and the urgent need for increased support. Her insights emphasize the importance of investing in innovative research to improve patient outcomes. #LungCancerResearch
March 15, 2025 at 6:15 PM
Dr. Kellie Smith highlights the critical issue of underfunding in lung cancer research and the urgent need for increased support. Her insights emphasize the importance of investing in innovative research to improve patient outcomes. #LungCancerResearch
Urgent! The U.S. House will vote TOMORROW on a bill that includes a 57% CUT to the Congressionally Directed Medical Research Programs (CDMRP), including #lungcancerresearch. Contac your rep NOW and tell them to vote NO on these harmful cuts. www.votervoice.net/LUNGevity/ca... #TakeAction
LAN News | LUNGevity Foundation
www.votervoice.net
March 10, 2025 at 1:33 PM
Urgent! The U.S. House will vote TOMORROW on a bill that includes a 57% CUT to the Congressionally Directed Medical Research Programs (CDMRP), including #lungcancerresearch. Contac your rep NOW and tell them to vote NO on these harmful cuts. www.votervoice.net/LUNGevity/ca... #TakeAction
We're grateful for the scientific discoveries and continued progress made possible by funding #LungCancerResearch. Learn about recent approvals for treatment: LCRF.org/FDA. Fund more research this Lung Cancer Awareness Month! LCRF.org/LCAMyourWay #LCAM2024 #Thankful
November 27, 2024 at 3:00 PM
We're grateful for the scientific discoveries and continued progress made possible by funding #LungCancerResearch. Learn about recent approvals for treatment: LCRF.org/FDA. Fund more research this Lung Cancer Awareness Month! LCRF.org/LCAMyourWay #LCAM2024 #Thankful
Dr. Stella Martinez highlighted research on risk factors associated with nodal upstaging during #LALCA25.
Find out more in ILCN: bit.ly/4klePuf #LCSM #LungCancerResearch
Find out more in ILCN: bit.ly/4klePuf #LCSM #LungCancerResearch
Study Finds Correlations Between Certain Factors, Rates of Nodal Upstaging - ILCN.org (ILCN/WCLC)
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America.
bit.ly
March 5, 2025 at 6:15 PM
Dr. Stella Martinez highlighted research on risk factors associated with nodal upstaging during #LALCA25.
Find out more in ILCN: bit.ly/4klePuf #LCSM #LungCancerResearch
Find out more in ILCN: bit.ly/4klePuf #LCSM #LungCancerResearch
Immunotherapy helps the immune system recognize and attack cancer cells. New research shows patients are seeing durable results that last long after treatment begins. Learn more about how this groundbreaking approach is advancing cancer treatment: buff.ly/Vgr158e
#Immunotherapy #LungCancerResearch
#Immunotherapy #LungCancerResearch
September 5, 2025 at 6:15 PM
Immunotherapy helps the immune system recognize and attack cancer cells. New research shows patients are seeing durable results that last long after treatment begins. Learn more about how this groundbreaking approach is advancing cancer treatment: buff.ly/Vgr158e
#Immunotherapy #LungCancerResearch
#Immunotherapy #LungCancerResearch
Dr. Jacob Kaufman explains how each biomarker in lung cancer can lead to a treatment designed specifically for patients with that marker. Learn more about the impact of biomarker testing in lung cancer today: buff.ly/OpJwidX
#LungCancer #Biomarker #LungCancerResearch
#LungCancer #Biomarker #LungCancerResearch
September 13, 2025 at 6:15 PM
Dr. Jacob Kaufman explains how each biomarker in lung cancer can lead to a treatment designed specifically for patients with that marker. Learn more about the impact of biomarker testing in lung cancer today: buff.ly/OpJwidX
#LungCancer #Biomarker #LungCancerResearch
#LungCancer #Biomarker #LungCancerResearch
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. China saw a 45% risk reduction, while Western results were not statistically significant. #LungCancerResearch #News
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. Chin...
www.statnews.com
September 7, 2025 at 10:08 PM
Summit Therapeutics' lung cancer drug, ivonescimab, showed varying efficacy in a recent study. China saw a 45% risk reduction, while Western results were not statistically significant. #LungCancerResearch #News
Bardic news brief for June 11, 2025. #schoolviolence #borderconflict #biotechinnovation #lungcancerresearch #climatepolicy #carbontrading #southeastasia #cleantechnology #renewableenergy #communitydevelopment #globalsustainability #grassrootsinnovation
June 11, 2025
YouTube video by DASGOE Media
youtube.com
June 11, 2025 at 10:17 AM
Every lung cancer treatment breakthrough begins with researchers in labs and clinical trials, working tirelessly to develop new therapies and opportunities for patients. Their dedication and discoveries are shaping the future of lung cancer care. #LungCancerResearch #ResearchHeroes
buff.ly/Mm2O1Bf
buff.ly/Mm2O1Bf
March 27, 2025 at 1:13 AM
Every lung cancer treatment breakthrough begins with researchers in labs and clinical trials, working tirelessly to develop new therapies and opportunities for patients. Their dedication and discoveries are shaping the future of lung cancer care. #LungCancerResearch #ResearchHeroes
buff.ly/Mm2O1Bf
buff.ly/Mm2O1Bf
Not every patient responds to immunotherapy in the same way. Dr. Kellie Smith explains which lung cancers are more likely to benefit and how doctors use testing to guide treatment decisions. Watch the full video here: buff.ly/OqAoIZh
#Immunotherapy #LungCancerResearch #LungCancer
#Immunotherapy #LungCancerResearch #LungCancer
September 7, 2025 at 6:15 PM
Not every patient responds to immunotherapy in the same way. Dr. Kellie Smith explains which lung cancers are more likely to benefit and how doctors use testing to guide treatment decisions. Watch the full video here: buff.ly/OqAoIZh
#Immunotherapy #LungCancerResearch #LungCancer
#Immunotherapy #LungCancerResearch #LungCancer
Dr. Christine Lovly is focused on pushing lung cancer research to deliver better, more precise treatments. Meet the researchers accelerating change in lung cancer care: buff.ly/aP93lFk #LungCancerResearch
April 13, 2025 at 3:03 PM
Dr. Christine Lovly is focused on pushing lung cancer research to deliver better, more precise treatments. Meet the researchers accelerating change in lung cancer care: buff.ly/aP93lFk #LungCancerResearch